Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.4x | 3.5x | −0.4x | |
PEG Ratio | −6.90 | 0.06 | 0.00 | |
Price/Book | 5.1x | 2.1x | 2.6x | |
Price / LTM Sales | - | 1.3x | 3.1x | |
Upside (Analyst Target) | 16.2% | 65.8% | 58.6% | |
Fair Value Upside | Unlock | 23.8% | 8.2% | Unlock |